18 jun: Ny opdateret BMW 7-serie
19 jun: Dansk storvildtjæger vækker opsigt internationalt
18-06-2012 10:45:00

Orbis Supports Vodafone Offer For C&WW

Relateret indhold

-- Orbis Investment Management supports Vodafone's GBP1.04B offer

-- Orbis had previously said 38p a share offer "didn't reflect inherent value" in C&WW

-- Orbis's assent paves way for the deal to clear

LONDON--U.K. telecommunications operator Cable & Wireless Worldwide PLC (CW.LN) Monday secured approval for an agreed 1.04 billion pound ($1.63 billion) takeover by mobile giant Vodafone Group PLC (VOD.LN) after its largest shareholder, Orbis Investment Management Ltd., swung behind the deal.

Canadian investor Orbis, which has a roughly 19% stake in C&WW, had been holding out until an investor meeting later today to disclose its intentions after earlier casting doubt on whether it would support the deal. Its support paves the way for the deal to close, allowing Vodafone to use the C&WW business to create a fixed-line business in the U.K.

Vodafone's 38 pence-a-share offer required the support of a 75% majority of C&WW's investors.

C&WW earlier Monday said it had received support for the deal from just under 59% of its remaining shareholders, based on proxy votes cast ahead of the meeting, but that it was waiting to hear what Orbis's intentions were.

Vodafone agreed in April to buy C&WW in a bid to transform the purely mobile player into the U.K.'s second-biggest mobile and fixed-line operator behind BT Group PLC. (BT.A.LN)

Shares in C&WW rose in early trading Monday, reflecting relief that Orbis had agreed to back the deal and by 0725 GMT were trading up by just under 8% at close to the 38 pence offer price in London.

C&WW, which was spun out of its parent group Cable & Wireless PLC in early 2010, had seen its share price battered after a series of profits warnings prior to receiving interest from Vodafone and Tata Communications, a unit of the Indian conglomerate, earlier this year. Vodafone announced its agreed deal in April after Tata withdrew from talks with C&WW.

Orbis, in an statement after the agreed Vodafone deal, said the for C&WW "does not appear to reflect the value inherent" in C&WW.

Monday, Orbis said that,following talks with C&WW over the weekend, it expected the bid would eventually succeed even if Orbis were to vote against it.

"In these circumstances, our opposition would only serve to prolong the process because the Company would likely adjourn today's meetings to secure the necessary votes. This is not in the interests of any CWW stakeholder."

-Write to jessica.hodgson@dowjones.com

(END) Dow Jones Newswires

June 18, 2012 04:45 ET (08:45 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/middag: Genmab buldrer frem med WDH og ISS som følgesvende

22-02-2018 11:40:57
Biotekselskabet Genmab ligger helt i top i det danske eliteindeks torsdag middag efter at have præsenteret regnskab onsdag aften. Også ISS og William Demant, der begge kom med regnskab for fjerde kvartal torsdag morgen, er med i toppen.Men det er onsdagens regnskab fra Genmab, der trækker den helt store opmærksomhed, efter at biotekselskabet gjorde markedets bekymringer over en mulig skuffende pro..

ISS: Salget vokser mens bundlinjen skrumper

22-02-2018 08:39:00
ISS kan se bundlinjen falde tilbage i 2017 sammenlignet med i 2016, selvom selskabet er vokset på salget.Omsætningen i selskabet voksede til 79.912 mio. kr. i 2017, mens omsætningen udgjorde 78.658 mio. kr. i 2016.Omvendt steg nettoresultatet i 2017 til 2007 mio. kr. mod 2220 mio. kr. året før.Af regnskabet fremgår det, at årsagen til at bundlinjen ikke vokser med toplinjen, blandt andet er ekster..

Novo Nordisk: Ozempic optaget på stor indkøbsforenings tilskudsliste

21-02-2018 15:39:04
Novo Nordisks nylancerede ugentlige GLP-1-analog Ozempic er blevet optaget på den amerikanske indkøbsforening Express Scripts nationale tilskudsliste, der gælder for en lang række sygekasser i 2018.Det bekræfter Novo Nordisk over for Ritzau Finans.Optagelsen er et vigtigt skridt i Novos arbejde med at indgå kontrakter med de store indkøbsforeninger, der står for sygekassernes indkøb og også rådgiv..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Mærsk/Sydbank: Aktionærer kan se frem til udbetaling i 2018 eller 2019
2
Genmab/Sydbank: Stærk Darzalex-prognose bør sende aktien op
3
Aktier/åbning: Genmab brager frem og trækker eliteindekset i plus
4
Vestas vinder mølleordre i USA
5
Aktier/tendens: Genmab, ISS og William i fokus i rød handelsstart

Relaterede aktiekurser

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. februar 2018 13:48:03
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20180222.1 - EUROWEB5 - 2018-02-22 13:48:03 - 2018-02-22 13:48:03 - 1 - Website: OKAY